Gland volume and PSA PAP
concentration in patients with BPH (benign prostatic hyperplasia)
Article published in Urologia Polska 1994/47/3.
authors
-
Jan Kulpa 2, Andrzej Bugajski 1, Ewa Wójcik 2, Janusz Jaszczyński 1
- 1 Zakład Analityki i Biochemii Klinicznej, Centrum Onkologii, Oddział w Krakowie
Kierownik: Dr chem. J. Kulpa
Dyrektor: Doc. dr hab. J. Skołyszewski
2 Katedra i Klinika Urologii, Collegium Medicum UJ w Krakowie
Kierownik: Doc. dr hab. med. A. Bugajski
summary
- Group of 406 patients with BPH — 164 of them with inflamation lesion and 50 of them
- with abscess have been examined. PAP and PSA concentrations have been observed and
- described concerning age groups, volume and weight of the resected gland. Higher concent-
- rations of PAP in plasma has been observed in 13,5% and that of PSA in 76,4% patients.
- PSA concentrations depended on gland weight (r =0,387-p<0,001). No relationship
- between PSA and PAP concentration and the patients\' age, and between the gland weight and
- the patients\' age has been found. However, relationship between PSA and PAP concentration
- r = 0,415 p<0,001
- Inflamation lesion and abscess of BHP prostate gland have got influence on the increase of
- PSA concentration as well as on gland volume.
references
- 1.Armitage T.G., Cooper E.H., Newling D.W.W., Robinson M.R.G., Appleyard /.: The value of the measurement of serum prostate specific antigen in patients with benign prostatic hyperplasia and untreated prostate cancer. Br. J. Urol., 1988, 62, 584. —
- 2. Bilhartz D.L., Tindall D.J., Oesterling J.E.: Prostate-specific antigen and prostatic acid phosphatase: Biomolecular and Physiologic characteristics. Urology, 1991, 38, 95.
- 3. Brawer M.K., Lange P.H.: Prostate-specific antigen: its role in early detection, staging, and monitoring of prostatic carcinoma. J. Endocr., 1989, 3, 227. —
- 4. Brown P.N., Speights V.O., Kuhl D., Riggs M., Spiekerman AM., McCord R.G., Coffield K.S., Stewart D.T., Und M.L.: Prostate-specific antigen levels from completely sectioned, Clinically benign, whole prostates. Cancer, 1991, 68,1592.
- 5. Carter H.B., Pearson J.D., Metler J.E., Brant L.J., Chan D.W., Andres R., Fozard J.L., Walsh P.C.: Longitudinal evaluation of Prostate-specific antigen levels in men with and without prostate disease. Jama, 1992, 267, 2215. —
- 6. Collins G.N., Lee R.J., McKefoie G.B., Rogers A.C.N., Henir M.\\\\ Relationship between prostate specific antigen, prostate volume and age in the benign prostate. Br. J. Urol., 1993, 71, 445. —
- 7. Cooner W.H., Mosley B.R., Rutherford CL., Beard J.H., Pond H.S., Bass R.B., Terry W.J.:Clinical application of transrectal ultrasonography and Prostate-specific antigen in the search for prostate cancer. J. Urol., 1988, 139, 758. —
- 8. Ferro M.A., Barnes /., Roberts J.B.M., Smith P.J.B.: Tumour markers in prostatic carcinoma. A Comparison of prostate — specific antigen with acid phosphatase. Br. J. Urol., 1987, 60, 69.
- 9. Geller J.: Basis for hormonal management of advanced prostate cancer. Cancer, 1993, 71 Suupl., 1039. — 10. Gittes R.F.: Carcinoma of the prostate. N. Engl. J. Med., 1991, 324, 236.
- 11.Heller J.E.: Prostatic acid phosphatase: its current clinical status. J. Urol. 1987, 137,1091.
- 12. Holmang S., Lindstedt G., Marin P., Hedelin H.:Serum concentration of Prostatic-specific antigen in relation t prostate volume in 50 healthy middle-aged men. Scand. J. Urol. Nephrol., 1993, 27, 15. —
- 13. Howanitz J.H.: Prostate specific antigen. Dis. Markers, 1993, 11, 3. —
- 14. Kane R.A., Littrup P.J., Babaian R., Drago J.R., Lee F., Chesley A., Murphy G.P., Mettlin C: Prostate-specific antigen levels in 1695 men without evidence of prostate cancer. Cancer, 1992, 69, 1201. —
- 15. Kulpa J., Marczyńska A., Wójcik E., Bugajski A., Leńko J.: Ocena stężenia swoistego antygenu sterczowego (PSA) w osoczu chorych na raka stercza. Urol. Pol., 1989, 42, 1.
- 16. Lee F., Torp-Pedersen S., Littrup P.J., McLeary R.D., McHugh T.A., Smid A.P., Stella P.J., Borlaza G.S.: Hypoechonic lesions of the prostate: clinical relevance of tumor size, digital rectal examination, and Prostate-specific antigen. Radiol., 1989, 170, 29. —
- 17. Leissner K.H., Tisell L.E.: The weight of the human prostate. Scand. J. Urol. Nephrol., 1979, 13, 137. —
- 18. Morote J., Ruibal A., Palou J., de Torres J.A., Soler-Rosello A.: Clinical utility of prostatic specific antigen and prostatic acid phosphatase serum levels in monitoring prostate cancer. Int. J. Biol. Markers, 1988, 3, 23. — 19. Oesterling J.E.: Prostate specific antigen: A critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J. Urol., 1991, 145, 907. —
- 20. Partin A.W., Carter H.B., Chan D.W., Epstein J.I., Oesterling J.E., Rock R.C., Weber J.P., Walsh P.C: Prostate specific antigen in the staging of localized prostate cancer: Influence of tumor differentiation, tumor volume and benign hyperplasia. J. Urol., 1990, 143, 747.
- 21. Pretlow T., Pretlow P.T., Yang B., Kaetzel CS., Delmoro C.M., Famis S.M., Bodner D.R., Kursh E., Resnick M.I., Bradley E.L.: Tissue concentrations of Prostate-specific antigen in prostatic carcinoma and benign hyperplasia. Int. J. Cancer, 1991, 49, 645. —
- 22. Rainwater L.M., Morgan W.R., Klee G.G., Zincke H.: Prostate-specific antigen testing in untreated and treated prostatic adenocarcinoma. Mayo Clin. Proc, 1990, 65, 1118. —
- 23.Stamey T.A., Yang N., Hay A.R., McNeal J.E., Frehia F.S., Redwin E.\\\\ Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. New Engl. J. Med., 1987, 317,909. —
- 24. Wang M.C, Loor R.M., Chu T.M.: Physico-chemical characterization of prostate antigen purified from human prostate gland and seminal plasma. Obst. Gynecol., 1983, 11, 327.
- 25. Weber J.P., Oesterling J.E., Peters CA., Partin A.W., Chan D.W., Walsh P.C.: The influence on serum Prostate-specific hyperplasia. J. Urol., 1989, 141, 987
correspondence
dr Jan Kulpa
Zakład Analityki i Biochemii Klinicznej,
Centrum Onkologii, Oddział w Krakowie
31-115 Kraków, ul. Garncarska 11
|